186 related articles for article (PubMed ID: 11902809)
1. Simvastatin and lovastatin, but not pravastatin, interact with MDR1.
Sakaeda T; Takara K; Kakumoto M; Ohmoto N; Nakamura T; Iwaki K; Tanigawara Y; Okumura K
J Pharm Pharmacol; 2002 Mar; 54(3):419-23. PubMed ID: 11902809
[TBL] [Abstract][Full Text] [Related]
2. Interaction of digoxin with antihypertensive drugs via MDR1.
Takara K; Kakumoto M; Tanigawara Y; Funakoshi J; Sakaeda T; Okumura K
Life Sci; 2002 Feb; 70(13):1491-500. PubMed ID: 11895100
[TBL] [Abstract][Full Text] [Related]
3. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K
Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
[TBL] [Abstract][Full Text] [Related]
4. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
5. Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport.
Takara K; Sakaeda T; Kakumoto M; Tanigawara Y; Kobayashi H; Okumura K; Ohnishi N; Yokoyama T
Oncol Res; 2009; 17(11-12):527-33. PubMed ID: 19806783
[TBL] [Abstract][Full Text] [Related]
6. MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs.
Kakumoto M; Takara K; Sakaeda T; Tanigawara Y; Kita T; Okumura K
Biol Pharm Bull; 2002 Dec; 25(12):1604-7. PubMed ID: 12499648
[TBL] [Abstract][Full Text] [Related]
7. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.
Newman A; Clutterbuck RD; Powles RL; Catovsky D; Millar JL
Leuk Lymphoma; 1997 Feb; 24(5-6):533-7. PubMed ID: 9086443
[TBL] [Abstract][Full Text] [Related]
9. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells.
Riessen R; Axel DI; Fenchel M; Herzog UU; Rossmann H; Karsch KR
Basic Res Cardiol; 1999 Oct; 94(5):322-32. PubMed ID: 10543307
[TBL] [Abstract][Full Text] [Related]
10. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
[TBL] [Abstract][Full Text] [Related]
11. Interaction of docetaxel ("Taxotere") with human P-glycoprotein.
Shirakawa K; Takara K; Tanigawara Y; Aoyama N; Kasuga M; Komada F; Sakaeda T; Okumura K
Jpn J Cancer Res; 1999 Dec; 90(12):1380-6. PubMed ID: 10665657
[TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.
Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
Biol Pharm Bull; 1999 Dec; 22(12):1355-9. PubMed ID: 10746169
[TBL] [Abstract][Full Text] [Related]
13. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Serajuddin AT; Ranadive SA; Mahoney EM
J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
[TBL] [Abstract][Full Text] [Related]
14. The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein.
Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
Jpn J Cancer Res; 2000 Feb; 91(2):248-54. PubMed ID: 10761713
[TBL] [Abstract][Full Text] [Related]
15. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
Wang E; Casciano CN; Clement RP; Johnson WW
Pharm Res; 2001 Jun; 18(6):800-6. PubMed ID: 11474784
[TBL] [Abstract][Full Text] [Related]
16. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil.
Kakumoto M; Sakaeda T; Takara K; Nakamura T; Kita T; Yagami T; Kobayashi H; Okamura N; Okumura K
Cancer Sci; 2003 Jan; 94(1):81-6. PubMed ID: 12708479
[TBL] [Abstract][Full Text] [Related]
17. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
Chen C; Mireles RJ; Campbell SD; Lin J; Mills JB; Xu JJ; Smolarek TA
Drug Metab Dispos; 2005 Apr; 33(4):537-46. PubMed ID: 15616150
[TBL] [Abstract][Full Text] [Related]
18. [Effect of the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A reductase, pravastatin and simvastatin, on colony formation by hematopoietic progenitor cells].
Kunitama M; Komatsu N; Miura Y
Rinsho Ketsueki; 1996 Nov; 37(11):1314-7. PubMed ID: 8960668
[TBL] [Abstract][Full Text] [Related]
19. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Oi S; Haneda T; Osaki J; Kashiwagi Y; Nakamura Y; Kawabe J; Kikuchi K
Eur J Pharmacol; 1999 Jul; 376(1-2):139-48. PubMed ID: 10440099
[TBL] [Abstract][Full Text] [Related]
20. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle.
van Vliet AK; Nègre-Aminou P; van Thiel GC; Bolhuis PA; Cohen LH
Biochem Pharmacol; 1996 Nov; 52(9):1387-92. PubMed ID: 8937448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
